Skip to main content

Advertisement

SpringerLink
Log in

Endothelial Damage and Regeneration: The Role of the Renin-Angiotensin-Aldosterone System

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

The renin-angiotensin-aldosterone system (RAAS) is part of the blood pressure regulating system. Its main effector peptide is angiotensin II (Ang II). Although it may induce hypertension, the proinflammatory, profibrotic, and prothrombotic effects are mainly mediated by effects of Ang II on the cellular and molecular level that are independent of blood pressure. Therefore, pharmacotherapeutic intervention within the RAAS is an important treatment modality for patients suffering from cardiovascular diseases, even those who are not hypertensive. In addition to the blood pressure lowering and vasculoprotective (pleiotropic) effects of angiotensin II type 1 (AT1) receptor blockers (ARBs), and angiotensin-converting enzyme (ACE) inhibitors, regenerative progenitor cell therapy emerges as an auxiliary therapy to improve regeneration of the vascular endothelium. This review focuses on the growing knowledge about regenerating vascular cells, their response to RAAS effectors, and RAAS-modulating pharmacotherapy in the context of endothelial cell damage and regeneration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Wassmann S, Nickenig G. Pathophysiological regulation of the AT1-receptor and implications for vascular disease. J Hypertens Suppl 2006; 24:S15–S21.

    Article  CAS  PubMed  Google Scholar 

  2. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med 1999; 340:115–126.

    Article  CAS  PubMed  Google Scholar 

  3. Suzuki Y, Ruiz-Ortega M, Lorenzo O, et al. Inflammation and angiotensin II. Int J Biochem Cell Biol 2003; 35(6):881–900.

    Article  CAS  PubMed  Google Scholar 

  4. • Sata M, Fukuda D. Crucial role of renin-angiotensin system in the pathogenesis of atherosclerosis. J Med Invest 2010; 57(1–2):12–25. This review reports on the critical role of Ang II in the initiation and progression of atherosclerosis.

    Article  PubMed  Google Scholar 

  5. Warnholtz A, Nickenig G, Schulz E, et al. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation 1999; 99(15):2027–33.

    CAS  PubMed  Google Scholar 

  6. Marino F, Guasti L, Cosentino M, et al. Simvastatin treatment in subjects at high cardiovascular risk modulates AT1R expression on circulating monocytes and T lymphocytes. J Hypertens 2008; 26(6):1147–55.

    Article  CAS  PubMed  Google Scholar 

  7. Wang YX. Cardiovascular functional phenotypes and pharmacological responses in apolipoprotein E deficient mice. Neurobiol Aging 2005; 26(3):309–16.

    Article  CAS  PubMed  Google Scholar 

  8. Urbich C, Dimmeler S. Risk factors for coronary artery disease, circulating endothelial progenitor cells, and the role of HMG-CoA reductase inhibitors. Kidney Int 2005; 67(5):1672–6.

    Article  CAS  PubMed  Google Scholar 

  9. Endtmann C, Ebrahimian T, Bohner A, et al. Angiotensin II impairs endothelial progenitor cell number and function in vitro and in vivo: implications for vascular regeneration [abstract V617]. Presented at the DGK Congress. Mannheim, Germany; April 8–10, 2010.

  10. Herbert KE, Mistry Y, Hastings R, et al. Angiotensin II-mediated oxidative DNA damage accelerates cellular senescence in cultured human vascular smooth muscle cells via telomere-dependent and independent pathways. Circ Res 2008;102(2):201–8.

    Article  CAS  PubMed  Google Scholar 

  11. Seeger FH, Sedding D, Langheinrich AC, et al. Inhibition of the p38 MAP kinase in vivo improves number and functional activity of vasculogenic cells and reduces atherosclerotic disease progression. Basic Res Cardiol 2010; 105(3):389–97.

    Article  CAS  PubMed  Google Scholar 

  12. Min LJ, Mogi M, Iwanami J, Li JM, et al. Angiotensin II type 2 receptor deletion enhances vascular senescence by methyl methanesulfonate sensitive 2 inhibition. Hypertension 2008; 51(5): 1339–44.

    Article  CAS  PubMed  Google Scholar 

  13. Pirro M, Schillaci G, Bagaglia F, et al. Microparticles derived from endotheial progenitor cells in patients at different cardiovascular risk. Atherosclerosis 2008;197:757–67.

    Article  CAS  PubMed  Google Scholar 

  14. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275(5302):964–7.

    Article  CAS  PubMed  Google Scholar 

  15. Asahara T, Masuda H, Takahashi T, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999; 85:221–228.

    CAS  PubMed  Google Scholar 

  16. Peichev M, Naiyer AJ, Pereira D, et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 2000; 95(3):952–8.

    CAS  PubMed  Google Scholar 

  17. Prater DN, Case J, Ingram DA, Yoder MC. Working hypothesis to redefine endothelial progenitor cells. Leukemia 2007 Jun;21(6):1141–9.

    Article  CAS  PubMed  Google Scholar 

  18. Yoder MC. Defining human endothelial progenitor cells. J Thromb Haemost 2009 Jul; 7 Suppl 1:49–52.

    Article  CAS  PubMed  Google Scholar 

  19. Critser PJ, Yoder MC. Endothelial colony-forming cell role in neoangiogenesis and tissue repair. Curr Opin Organ Transplant 2010; 15(1):68–72.

    Article  PubMed  Google Scholar 

  20. Hur J, Yoon CH, Kim HS, et al. Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arterioscler Thromb Vasc Biol 2004; 24(2):288–93.

    Article  CAS  PubMed  Google Scholar 

  21. Sieveking DP, Buckle A, Celermajer DS, Ng MK. Strikingly different angiogenic properties of endothelial progenitor cell subpopulations: insights from a novel human angiogenesis assay. J Am Coll Cardiol 2008; 51(6):660–8.

    Article  CAS  PubMed  Google Scholar 

  22. Case J, Mead LE, Bessler WK, et al. Human CD34 + AC133 + VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. Exp Hematol 2007; 35(7):1109–18.

    Article  CAS  PubMed  Google Scholar 

  23. Elsheikh E, Uzunel M, He Z, et al. Only a specific subset of human peripheral-blood monocytes has endothelial-like functional capacity. Blood 2005 Oct 1; 106(7):2347–55. Epub 2005 Jun 28.

    Article  CAS  PubMed  Google Scholar 

  24. Hirschi KK, Ingram DA, Yoder MC. Assessing identity, phenotype, and fate of endothelial progenitor cells. Arterioscler Thromb Vasc Biol 2008 Sep; 28(9):1584–95. Epub 2008 Jul 31. Review.

    Article  CAS  PubMed  Google Scholar 

  25. Werner N, Nickenig G. Endothelial progenitor cells in health and atherosclerotic disease. Ann Med 2007; 39:82–90.

    Article  CAS  PubMed  Google Scholar 

  26. Shi RZ, Wang JC, Huang SH, et al. Angiotensin II induces vascular endothelial growth factor synthesis in mesenchymal stem cells. Exp Cell Res 2009 Jan 1; 315(1):10–5.

    Article  CAS  PubMed  Google Scholar 

  27. Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003; 348:593–600.

    Article  PubMed  Google Scholar 

  28. Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005; 353:999–1007.

    Article  CAS  PubMed  Google Scholar 

  29. Werner N, Wassmann S, Ahlers P, et al. Endothelial progenitor cells correlate with endothelial function in patients with coronary artery disease. Basic Res Cardiol 2007; 102:565–571.

    Article  PubMed  Google Scholar 

  30. Cheng S, Cohen KS, Shaw SY, et al. Association of Colony-Forming Units with Coronary Artery and Abdominal Aortic Calcification. Circulation. 2010 Sep 7 (Epub ahead of print).

  31. Yoder MC, Mead LE, Prater D, et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 2007; 109(5):1801–9.

    Article  CAS  PubMed  Google Scholar 

  32. Rosamond W, Flegal K, Friday G. Heart and stroke statistics 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007; 115, e69–e171.

    Article  PubMed  Google Scholar 

  33. •• Mann JF, Schmieder RE, McQueen M, et al.; ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372(9638):547–53. This trial analyzed whether ARBs and ACE inhibitors in combination might be more effective than either treatment alone in people at high vascular risk. Although combination therapy reduced proteinuria to a greater extent than monotherapy, the combination worsens major outcomes overall.

    Article  CAS  PubMed  Google Scholar 

  34. HOPE Study Organisation. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355(9200):253–9.

    Article  Google Scholar 

  35. •• Qian C, Schoemaker RG, van Gilst WH, Roks AJ. The role of the renin-angiotensin-aldosterone system in cardiovascular progenitor cell function. Clin Sci (Lond) 2009; 116(4):301–14. This is a state-of-the-art review focusing on regenerative progenitor cell therapy with respect to the role of the RAAS.

    Article  CAS  Google Scholar 

  36. Bahlmann FH, de Groot K, Mueller O, et al. Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists. Hypertension 2005; 45(4):526–9.

    Article  CAS  PubMed  Google Scholar 

  37. Yu Y, Fukuda N, Yao EH, et al. Effects of an ARB on endothelial progenitor cell function and cardiovascular oxidation in hypertension. Am J Hypertens 2008, 21:72–77.

    Article  CAS  PubMed  Google Scholar 

  38. Müller P, Kazakov A, Jagoda P, et al. ACE inhibition promotes upregulation of endothelial progenitor cells and neoangiogenesis in cardiac pressure overload. Cardiovasc Res 2009;83(1):106–14.

    Article  PubMed  Google Scholar 

  39. Rauscher FM, Goldschmidt-Clermont PJ, Davis BH, et al. Aging, progenitor cell exhaustion, and atherosclerosis. Circulation 2003; 108:457–463.

    Article  PubMed  Google Scholar 

  40. • Honda A, Matsuura K, Fukushima N, et al. Telmisartan induces proliferation of human endothelial progenitor cells via PPARγ-dependent PI3K/Akt pathway. Atherosclerosis 2009; 205(2):376–84. This paper investigates the effects of telmisartan on endothelial integrity and vasculogenesis.

    Article  CAS  PubMed  Google Scholar 

  41. Cherney DZ, Lai V, Scholey JW, et al. Effect of direct renin inhibition on renal hemodynamic function, arterial stiffness, and endothelial function in humans with uncomplicated type 1 diabetes: a pilot study. Diabetes Care 2010; 33(2):361–5.

    Article  CAS  PubMed  Google Scholar 

  42. Lu H, Rateri DL, Feldman DL, Jr RJ, et al. Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J Clin Invest 2008; 118(3):984–93.

    CAS  PubMed  Google Scholar 

  43. van Esch JH, Moltzer E, van Veghel R, et al. Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats. J Hypertens 2010; 28(10):2145–55.

    PubMed  Google Scholar 

  44. Negro R. Endothelial effects of antihypertensive treatment: focus on irbesartan. Vasc Health Risk Manag 2008; 4(1):89–101.

    Article  CAS  PubMed  Google Scholar 

  45. Martinez FA. Aldosterone Inhibition and Cardiovascular Protection: More Important Than it Once Appeared. Cardiovasc Drugs Ther 2010; 24(4):345–50.

    Article  CAS  PubMed  Google Scholar 

  46. Marumo T, Uchimura H, Hayashi M, et al. Aldosterone impairs bone marrow-derived progenitor cell formation. Hypertension 2006; 48:490–496.

    Article  CAS  PubMed  Google Scholar 

  47. Verhovez A, Zeoli A, Williams TA, et al. Primary aldosteronism and endothelial progenitor cell bioavailability. Clin Endocrinol 2008; 69:528–34.

    Article  CAS  Google Scholar 

  48. • Thum T, Schmitter K, Fleissner F, et al. Impairment of endothelial progenitor cell function and vascularization capacity by aldosterone in mice and humans. Eur Heart J 2010 Oct 5 (Epub ahead of print). This paper demonstrates the effect of aldosterone on endothelial progenitor cell number and function in mice and humans.

  49. Haznedaroglu IC, Ozturk MA. Towards the understanding of the local hematopoietic bone marrow renin–angiotensin system. Int J Biochem Cell Biol 2003; 35:867–80.

    Article  CAS  PubMed  Google Scholar 

  50. Tousoulis D, Andreou I, Antoniades C, et al. Role of inflammation and oxidative stress in endothelial progenitor cell function and mobilization: therapeutic implications for cardiovascular diseases. Atherosclerosis 2008; 201(2):236–47.

    Article  CAS  PubMed  Google Scholar 

  51. Abali H, Haznedaroglu IC, Goker H, et al. Circulating and local bone marrow renin-angiotensin system in leukemic hematopoiesis: preliminary evidences. Hematology 2002; 7(2):75–82.

    Article  CAS  PubMed  Google Scholar 

  52. Cassis LA, Rateri DL, Lu H, Daugherty A. Bone marrow transplantation reveals that recipient AT1a receptors are required to initiate angiotensin II-induced atherosclerosis and aneurysms. Arterioscler Thromb Vasc Biol 2007; 27(2):380–6.

    Article  CAS  PubMed  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Medizinische Klinik und Poliklinik II, Universitätsklinikum Bonn, Sigmund-Freud-Str. 25, 53105, Bonn, Germany

    Ulrich M. Becher, Cathleen Endtmann, Vedat Tiyerili, Georg Nickenig & Nikos Werner

Authors
  1. Ulrich M. Becher
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cathleen Endtmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vedat Tiyerili
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Georg Nickenig
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nikos Werner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nikos Werner.

Additional information

Ulrich M. Becher and Cathleen Endtmann contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Becher, U.M., Endtmann, C., Tiyerili, V. et al. Endothelial Damage and Regeneration: The Role of the Renin-Angiotensin-Aldosterone System. Curr Hypertens Rep 13, 86–92 (2011). https://doi.org/10.1007/s11906-010-0171-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-010-0171-x

Keywords

Search

Navigation